Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies (Q35124674)

6 August 2017

1 reference

title

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies (English)

1 reference

6 August 2017

1 reference

1 reference

Alberto Gabizon

1

1 reference

6 August 2017

Hilary Shmeeda

series ordinal

2

1 reference

6 August 2017

Yechezkel Barenholz

series ordinal

3

1 reference

6 August 2017

1 January 2003

1 reference

Clinical Pharmacokinetics

6 August 2017

1 reference

6 August 2017

42

1 reference

6 August 2017

419-436

1 reference

6 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200342050-00002

6 August 2017

0 references

cites work

Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?

1 reference

12 December 2020

Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery

1 reference

12 December 2020

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.

1 reference

12 December 2020

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity

1 reference

12 December 2020

Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice

1 reference

12 December 2020

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

1 reference

12 December 2020

DRV liposomal bupivacaine: preparation, characterization, and in vivo evaluation in mice

1 reference

12 December 2020

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma

1 reference

12 December 2020

Gelation of liposome interior. A novel method for drug encapsulation

1 reference

12 December 2020

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

1 reference

12 December 2020

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

1 reference

12 December 2020

Development of liposomal anthracyclines: from basics to clinical applications

1 reference

12 December 2020

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs

1 reference

12 December 2020

Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models

1 reference

12 December 2020

Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study

1 reference

12 December 2020

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

1 reference

12 December 2020

Openings between defective endothelial cells explain tumor vessel leakiness

1 reference

12 December 2020

Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG)

1 reference

12 December 2020

Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

1 reference

12 December 2020

Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model

1 reference

12 December 2020

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes

1 reference

12 December 2020

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Targeting of drugs: implications in medicine

1 reference

12 December 2020

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Sterically stabilized liposomes

1 reference

12 December 2020

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

1 reference

12 December 2020

In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release

1 reference

12 December 2020

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

12 December 2020

Liposomal encapsulated anthracyclines: new therapeutic horizons

1 reference

12 December 2020

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

1 reference

12 December 2020

Uptake of small liposomes by non-reticuloendothelial tissues

1 reference

12 December 2020

Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft

1 reference

12 December 2020

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy

1 reference

12 December 2020

Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas

1 reference

12 December 2020

The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs

1 reference

12 December 2020

Pharmacokinetics of stealth versus conventional liposomes: effect of dose

1 reference

12 December 2020

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

12 December 2020

Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours

1 reference

12 December 2020

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

1 reference

12 December 2020

Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).

1 reference

12 December 2020

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

12 December 2020

Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery.

1 reference

12 December 2020

Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases

1 reference

12 December 2020

Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.

1 reference

12 December 2020

Phase I study of liposomal vincristine

1 reference

12 December 2020

Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines

1 reference

12 December 2020

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy

1 reference

12 December 2020

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models

1 reference

12 December 2020

Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer

1 reference

12 December 2020

Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles

1 reference

12 December 2020

Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.

1 reference

12 December 2020

Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.

1 reference

12 December 2020

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

1 reference

12 December 2020

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

1 reference

12 December 2020

Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes

1 reference

12 December 2020

Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes

1 reference

12 December 2020

High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours

1 reference

12 December 2020

10.2165/00003088-200342050-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference